Cargando…

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

Peripheral T cell lymphoma (PTCL) has a poor prognosis. Overexpression of vascular endothelial growth factor (VEGF) might contribute to the poor prognosis of PTCL and could be the target of novel therapy. The efficacy and safety of recombinant human endostatin (Endostar) in combination with cyclopho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qunling, Cao, Junning, Xue, Kai, Liu, Xiaojian, Ji, Dongmei, Guo, Ye, Hong, Xiaonan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189703/ https://www.ncbi.nlm.nih.gov/pubmed/28053548 http://dx.doi.org/10.2147/OTT.S117007

Ejemplares similares

Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma
por: Liu, Yizhen, et al.
Publicado: (2020)

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial
por: Jin, Jia, et al.
Publicado: (2022)

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T‐cell lymphoma patients
por: Liu, Yizhen, et al.
Publicado: (2020)

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study
por: Ji, Dongmei, et al.
Publicado: (2016)

Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial
por: Xue, Kai, et al.
Publicado: (2016)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma
por: Liu, Yizhen, et al.
Publicado: (2022)

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
por: Zhang, Yao, et al.
Publicado: (2021)

Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth
por: Zhang, Ke, et al.
Publicado: (2017)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer
por: Zhang, Chi, et al.
Publicado: (2015)

Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen
por: Chen, Xing-Gui, et al.
Publicado: (2011)

Endostatin and Oxaliplatin‐Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study
por: Li, Wenxin, et al.
Publicado: (2019)

Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy
por: Xue, Li-Jun, et al.
Publicado: (2010)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment
por: Li, Kai, et al.
Publicado: (2018)

A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
por: Arcari, Annalisa, et al.
Publicado: (2023)

Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice
por: Ma, Xingqun, et al.
Publicado: (2012)

Antiangiogenic effects of recombinant human endostatin in lung cancers
por: He, Lang, et al.
Publicado: (2018)

Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma
por: Chen, Guang-Liang, et al.
Publicado: (2022)

The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer
por: Liu, Yanyang, et al.
Publicado: (2016)

Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study
por: Ge, Jing-jing, et al.
Publicado: (2020)

A Case of Cutaneous T Cell Lymphoma Masquerading as Keloidal Blastomycosis Treated with CHOP Regimen
por: Reddy, Duttala Indira, et al.
Publicado: (2022)

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
por: Flinn, Ian W., et al.
Publicado: (2019)

Upcoming immunotherapeutic combinations for B-cell lymphoma
por: Greve, Patrick, et al.
Publicado: (2021)

Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017)

Real‐world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non‐driver gene mutation advanced non‐small cell lung cancer
por: Wang, Zhongtai, et al.
Publicado: (2019)

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
por: Wakasugi, Yoshinori, et al.
Publicado: (2019)

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014)

Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma
por: Choi, Eun-Ji, et al.
Publicado: (2017)

Endostatin in the pancreas
por: Wigmore, S J
Publicado: (2005)

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
por: Davies, Andrew J., et al.
Publicado: (2023)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
por: Feng, Li, et al.
Publicado: (2021)

Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma
por: Yang, Jing, et al.
Publicado: (2022)

Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
por: Wang, Shan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5m335oc02vh7ehmulljphhqv1f